Norepinephrine precursor therapy in neurogenic orthostatic hypotension

Area of Science:

• Neuroscience
• Pharmacology
• Cardiovascular Medicine

Background:

• Neurogenic orthostatic hypotension (NOH) is characterized by insufficient norepinephrine (NE) availability in the synaptic cleft, impairing blood pressure regulation upon standing.
• This deficiency significantly impacts patients' ability to maintain blood pressure in an upright posture.

Purpose of the Study:

• To investigate the efficacy of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in improving blood pressure and orthostatic tolerance in patients with severe NOH.
• To determine the mechanism by which L-DOPS exerts its pressor effects.

Main Methods:

• A dose-titration study identified optimal L-DOPS dosage in 19 NOH patients (8 with pure autonomic failure, 11 with multiple-system atrophy).
• A double-blind, placebo-controlled, crossover trial assessed the effects of L-DOPS on blood pressure and orthostatic tolerance.
• Plasma NE levels and the impact of carbidopa (an L-aromatic amino acid decarboxylase inhibitor) on L-DOPS response were evaluated.

Main Results:

• Oral L-DOPS administration significantly increased mean blood pressure in both supine and standing positions for several hours.
• Orthostatic tolerance was improved in all participating patients following L-DOPS treatment.
• Blood pressure increases correlated with elevated plasma NE levels, and carbidopa administration blunted both NE increase and pressor response.

Conclusions:

• Acute administration of L-DOPS effectively increases blood pressure and enhances orthostatic tolerance in NOH patients.
• The therapeutic effect of L-DOPS is attributed to its conversion into norepinephrine (NE) outside the central nervous system.